DXCM - 2 No-Brainer Growth Stocks to Buy Right Now
A discussion of "growth stocks" may not thrill investors quite the way it did just a year or two ago, but this type of investment is quite the horror show some make it out to be. Share prices are a bit more volatile across many sectors at the moment, but there are some great businesses still generating impressive financial results even as the threat of a recession grows.
Here are two no-brainer growth stocks still worthy of the designation to consider adding to your portfolio before the end of January.
DexCom (NASDAQ: DXCM) has a relatively small portfolio of products, with its flagship product being its G series of continuous glucose monitoring (CGM) devices. Its latest product is the G7 CGM. This was just approved in the U.S. in December and is currently being distributed across the U.K., Europe, and Asia, with expected launches in markets including South Africa, New Zealand, and others slated for the months ahead.
For further details see:
2 No-Brainer Growth Stocks to Buy Right Now